Nature Communications (Jul 2024)

A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma

  • Kang-Bo Huang,
  • Cheng-Peng Gui,
  • Yun-Ze Xu,
  • Xue-Song Li,
  • Hong-Wei Zhao,
  • Jia-Zheng Cao,
  • Yu-Hang Chen,
  • Yi-Hui Pan,
  • Bing Liao,
  • Yun Cao,
  • Xin-Ke Zhang,
  • Hui Han,
  • Fang-Jian Zhou,
  • Ran-Yi Liu,
  • Wen-Fang Chen,
  • Ze-Ying Jiang,
  • Zi-Hao Feng,
  • Fu-Neng Jiang,
  • Yan-Fei Yu,
  • Sheng-Wei Xiong,
  • Guan-Peng Han,
  • Qi Tang,
  • Kui Ouyang,
  • Gui-Mei Qu,
  • Ji-Tao Wu,
  • Ming Cao,
  • Bai-Jun Dong,
  • Yi-Ran Huang,
  • Jin Zhang,
  • Cai-Xia Li,
  • Pei-Xing Li,
  • Wei Chen,
  • Wei-De Zhong,
  • Jian-Ping Guo,
  • Zhi-Ping Liu,
  • Jer-Tsong Hsieh,
  • Dan Xie,
  • Mu-Yan Cai,
  • Wei Xue,
  • Jin-Huan Wei,
  • Jun-Hang Luo

DOI
https://doi.org/10.1038/s41467-024-50369-y
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Integrating genomics and histology for cancer prognosis demonstrates promise. Here, we develop a multi-classifier system integrating a lncRNA-based classifier, a deep learning whole-slide-image-based classifier, and a clinicopathological classifier to accurately predict post-surgery localized (stage I–III) papillary renal cell carcinoma (pRCC) recurrence. The multi-classifier system demonstrates significantly higher predictive accuracy for recurrence-free survival (RFS) compared to the three single classifiers alone in the training set and in both validation sets (C-index 0.831-0.858 vs. 0.642-0.777, p < 0.05). The RFS in our multi-classifier-defined high-risk stage I/II and grade 1/2 groups is significantly worse than in the low-risk stage III and grade 3/4 groups (p < 0.05). Our multi-classifier system is a practical and reliable predictor for recurrence of localized pRCC after surgery that can be used with the current staging system to more accurately predict disease course and inform strategies for individualized adjuvant therapy.